The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of imetelstat plus ruxolitinib for patients with intermediate-1, intermediate-2, or high-risk myelofibrosis demonstrated manageable safety and promising activity, according to interim results from the IMproveMF trial.
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
The combination of venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory acute myeloid leukemia, according to results from a phase 2 trial.
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
The US FDA approved linvoseltamab-gcpt for the treatment of adults with relapsed/refractory multiple myeloma based on results from the LINKER-MM1 clinical trial.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
